Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 128 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Transplant Recipients Clear all
Completed Not applicable Interventional

Adult Liver Transplant Enhanced Care

NCT02320422
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
Behavioral Telehealth
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Text Messages for Liver Transplant Recipients

NCT04995770
View directory record Official record
Conditions
Medication Adherence, Liver Transplant Disorder
Interventions
Praise Text Messages
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03639623
View directory record Official record
Conditions
Liver Transplant; Complications, NAFLD
Interventions
Saroglitazar
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Jul 22, 2026, 11:59 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jul 22, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

NCT00473824
View directory record Official record
Conditions
Sequelae of Viral Hepatitis, Transplantation Infection, Evidence of Liver Transplantation
Interventions
Hepatitis C Immune Globulin Intravenous (Human) 5%
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional Results available

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

NCT00336817
View directory record Official record
Conditions
Immunosuppression
Interventions
Myfortic, CellCept
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

NCT01624285
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
sorafenib tosylate, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients

NCT03650920
View directory record Official record
Conditions
Liver Failure
Interventions
Liver Transplantation
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 11:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant

NCT00585858
View directory record Official record
Conditions
Kidney Transplantation, Liver Transplantation
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

NCT03801707
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C, HCV
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Starzl Network Patient Reported Outcomes

NCT05241847
View directory record Official record
Conditions
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions
PeLTQL delivery via electronic means
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076
View directory record Official record
Conditions
Liver Disease
Interventions
mycophenolate mofetil
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Philadelphia, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Jul 22, 2026, 11:59 AM EDT
Recruiting Phase 2 Interventional

Defibrotide Dose-escalation for SOS Post-HSCT

NCT05987124
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
Interventions
Defibrotide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 11:59 AM EDT
Withdrawn No phase listed Observational

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303
View directory record Official record
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 22, 2026, 11:59 AM EDT
Completed No phase listed Observational

CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients

NCT03924219
View directory record Official record
Conditions
Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
Interventions
CMV T cell Immunity Assay
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
0 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 11:59 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

Belatacept in Liver Transplant Recipients

NCT00555321
View directory record Official record
Conditions
Immunosuppression in Solid Organ Transplant
Interventions
Tacrolimus, Basiliximab, Belatacept More Intensive (MI), Belatacept Less Intensive (LI), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Jul 22, 2026, 11:59 AM EDT
Active, not recruiting Phase 4 Interventional

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

NCT05325073
View directory record Official record
Conditions
Liver Transplant Rejection
Interventions
Erythropoietin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 74 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 3 Interventional

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

NCT00975702
View directory record Official record
Conditions
Kidney Disease, Liver Disease, Pancreas Disease
Interventions
RIPC by Inflation of Pneumatic Tourniquet
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients

NCT02739412
View directory record Official record
Conditions
Liver Transplantation
Interventions
Interleukin-2
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 22, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 22, 2026, 11:59 AM EDT
Terminated No phase listed Observational

Prediction of Hepatitis C Recurrence in Liver Transplant Recipients

NCT00867243
View directory record Official record
Conditions
Complication of Transplanted Liver, Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Jul 22, 2026, 11:59 AM EDT